À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉ磨×ܲ¿£º¶«¾©£¬Ê×ϯִÐй٣ºÄÚÌÙÇç·ò£¬ÒÔϼò³Æ¡°À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¡±£©½ñÈÕÐû²¼ÆäÔÚͬÐÐÆÀÒéÆÚ¿¯¡¶Éñ¾²¡Ñ§ÓëÖÎÁÆ¡·ÉÏ·¢±íÁËÒ»ÏîÔçÆÚÆÀ¹ÀµÄ½á¹û£¬¸ÃÆÀ¹ÀÖ¼ÔÚʹÓþÑéÖ¤µÄ¼²²¡Ä£ÄâÄ£ÐÍ–AD Archimedes Condition Event£¨AD ACE£©Ä£ÐÍ1,2,3£¬´ÓÃÀ¹úÒ½±£Ö§¸¶·½ºÍÉç»áµÄ½Ç¶ÈÀ´Ô¤¼Æ¿¹¦Âµí·ÛÑùÂÑ°×£¨A¦Â£©ÔÏËά¿¹ÌåLecanemabÔÚÖÎÁÆÔçÆÚ°¢¶û´Äº£Ä¬²¡£¨AD£©»¼ÕßµÄDZÔÚ¾¼Ã¼ÛÖµ¡£ÕâÊǵڶþƪ¹ØÓÚLecanemabDZÔÚ¼ÛÖµµÄÎÄÕ£¬ÉÏһƪÊǹØÓÚʹÓÃÄ£ÄâÄ£ÐͶÔLecanemabµÄºã¾Ã½¡¿µ½á¾Ö½øÐÐÆÀ¼Û£¬ÓÚ2022Äê4ÔÂÔÚ¡¶Éñ¾²¡Ñ§ÓëÖÎÁÆ¡·ÉÏ·¢±í4¡£Ò½±£Ö§¸¶·½½Ç¶ÈÖصã¹Ø×¢Ö±½Ó»¤ÀíÓöȣ¨ÈçÃÅÕïºÍסԺ·þÎñ¡¢Ò©Îï¡¢¸ÉÔ¤ÖÎÁÆÓöȡ¢ÁÆÑøÔººÍ¾Ó¼ÒÒ½ÁƱ£½¡·þÎñ£©£¬Éç»á½Ç¶ÈÔò½øÒ»²½¿¼ÂÇÁËÉç»á³É±¾£¨ÈçÉú²úÁ¦ËðʧºÍ·ÇÕýʽ»¤ÀíÓöȣ©¡£Èç֮ǰһƪÎÄÕÂËùÊö£¬Óë³ß¶ÈÖÎÁÆ*£¨SoC£©Ïà±È£¬ÔÚSoC»ù´¡ÉϼÓÓÃLecanemab£¨Lecanemab+SoC£©ÖÎÁƵĸöÌå´Ó»ùÏßµ½Çá¶È¡¢ÖжȺÍÖضÈADµÄ¼²²¡½øÕ¹¿ÉÄÜ»á¼õ»º£¬Æ½¾ù¼õ»ºÊ±¼ä·Ö±ðΪ2.51Äê¡¢3.13ÄêºÍ2.34Äê¡£ÕâÖÖ»ùÓÚÄ£Ð͵ÄÄ£Ä⿪¶Ë½á¹û¿ÉÄÜ»áÑÓ³¤ÖÊÁ¿µ÷ÕûÉúÃüÄ꣨QALY**£©£¬²¢¼õÉÙÕýʽºÍ·ÇÕýʽ»¤ÀíÓöÈ***¡£´ËÍ⣬±¾Ñо¿ÖÐʹÓõÄAD ACEÄ£ÐÍ¿ò¼ÜÓÐÖúÓÚÆÀ¹ÀLecanemabÔÚ²îÒìÇé¿öϵÄDZÔÚ¼ÛÖµÒÔ¼°½øÐÐÃô¸ÐÐÔ·ÖÎö£¬°üÂÞ»¼Õß×Ó¼¯¡¢Ìæ´úÖÎÁÆÍ£Ö¹¹æÔò****¡¢Ç±ÔÚ¸øÒ©·½°¸ÒÔ¼°Ö÷Òª²»È·¶¨ÐÔÀ´Ô´µÄÓ°Ïì¡£
À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ñз¢µÄLecanemab£¬Ö¼ÔÚ¸ÄÉÆÄÔÖÐÒÑ´æÔÚµí·ÛÑù²¡±äµÄÔçÆÚAD»¼ÕßµÄÔ¤ºó£¬Í¬Ê±ÖÂÁ¦ÓÚ¿ªÕ¹ºÍ·ÖÏíÏà¹ØÑо¿µÄÁÙ´²·ÖÎöºÍÉç»á¾¼Ãѧ·ÖÎö¡£Îª´Ë£¬À´Àû¹ú¼Êw66¹Ù·½ÍøվϣÍûΪÀûÒæÏà¹ØÕß´ÓÉç»á½Ç¶ÈÌÖÂÛLecanemabµÄDZÔÚÁÙ´²¼ÛÖµºÍÉç»á¾¼Ãѧ¼ÛÖµÌṩ»ù´¡£¬²¢ÔÝʱ²»ÎªLecanemab¶©¼Û¡£
ÕâÒ»»ùÓÚÄ£Ð͵ÄÄ£ÄâÀûÓÃÁËIIbÆÚÁÙ´²ÊÔÑ飨Ñо¿201£©µÄ½á¹û£¬¸ÃÊÔÑéÆÀ¼ÛÁËLecanemabÓÃÓÚÒÑ´æÔÚµí·ÛÑù²¡±äµÄÔçÆÚAD»¼ÕßµÄÁÆЧºÍÄþ¾²ÐÔ£¬²¢ÒÑ·¢±í¡£Æ仹ƾ¾ÝÁÙ´²ºÍ¾¼ÃÉó²éÑо¿Ëù£¨ICER£©*****µÄ½¨Ò飬Ôڹ㷺µÄÖ§¸¶ÒâÔ¸ãÐÖµ·¶Î§£¨50,000ÃÀÔª-200,000ÃÀÔª/QALY£©ÄÚÔ¤¼ÆÁËLecanemab+SoCµÄDZÔÚ¾¼Ã¼ÛÖµ¡£´ÓÒ½±£Ö§¸¶·½½Ç¶ÈÀ´¿´£¬¶ÔÓÚÈ·ÈÏ´æÔÚµí·ÛÑù²¡±äµÄÔçÆÚAD»¼ÕßÀ´Ëµ£¬Ïà±ÈÓÚSoC£¬Ô¤¼ÆLecanemab+SoC½«Ôö¼Ó0.61 QALY£¬·ÇÖÎÁÆ×ÜÓöȽ«¼õÉÙ8,707ÃÀÔª/ÈË£¨Éç»á½Ç¶È£ºÔö¼Ó0.64 QALY£¬¼õÉÙ11,214ÃÀÔª£©¡£Æ¾¾ÝÕâÒ»ÔçÆÚ¾¼ÃÆÀ¼Û£¬Ô¤¼ÆLecanemabµÄDZÔÚÄê¶È¼ÛÖµµ¼Ïò¶©¼Û(VBP)Ϊ9,249-35,605ÃÀÔª£¨Éç»á½Ç¶È£º10,400-38,053ÃÀÔª£©¡£
ICERµÄ¼ÛÖµ¿ò¼Ü5±íÃ÷£¬²»Äܽöƾ¾ÝÁÙ´²ºÍ³É±¾Ð§ÒæÖ¸±êÀ´ºâÁ¿¼ÛÖµ£¬Òò´ËÔÚÆÀ¹Àºã¾Ã¼Ûֵʱ£¬»¹ÒªÔÚ¿ò¼ÜÖмÓÈë¶ÔÅä¾°ÒòËØÒÔ¼°ÆäËû»ñÒæºÍµ¹Ã¹ÒòËصĿ¼Á¿¡£Ïà¶ÔÓÚÖ±½ÓÒ½ÁÆÓöȶøÑÔ£¬AD»¹¸øÉç»áÔì³ÉÁ˾޴󸺵££¬Õâ¿ÉÄܵ¼ÖÂÔÚÔ¤¼ÆLecanemabµÄºÏÀí¼Û¸ñʱ½ÓÄÉÉç»áÊӽDz¢Ìá¸ß¹ã·ºÖ§¸¶ÒâÔ¸ãÐÖµ·¶Î§µÄÉÏÏÞ¡£
Ðí¶àAD»¼Õß½ÓÊÜÁ˼ÒÈ˺ÍÅóÓѵķÇÕýʽ»¤Àí£¬2021ÄêÃÀ¹úÎÞ³¥»¤Àí×Üʱ¼äÁè¼Ý160ÒÚСʱ£¬¼ÛÖµ2716ÒÚÃÀÔª6¡£ÕâЩԤ²âºÍÄ£Äâ½á¹û±íÃ÷£¬ÔçÆÚʹÓÃLecanemabÖÎÁÆ¿ÉÄÜ»á¼õÉÙ´ËÀà³É±¾ºÍ¾¼Ã¸ºµ££¬²¢ÎªÒ½ÁƱ£½¡¾ö²ßÕßÌṩÓйØLecanemabDZÔÚÁÙ´²ºÍÉç»á¾¼Ãѧ¼ÛÖµµÄÉî¿Ì¼û½â¡£ÎÒÃǺܿì¾ÍÄÜ»ñµÃLecanemab IIIÆÚClarity ADÑо¿µÄÊý¾Ý£¬´Ó¶øΪģÐÍÊäÈëÌṩÐÅÏ¢²¢ÍêÉÆÑо¿½á¹û¡£Èç¹ûLecanemab»ñµÃÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©µÄÅú×¼£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¿ÉÄÜ»áʹÓÃÕâ¸ö¿ò¼ÜÒÔ¼°ÆäËû¿¼ÂÇÒòËØ£¨Èç¿É¸ºµ£ÐÔ¡¢ÎÀÉúϵͳµÄ¿ÉÁ¬ÐøÐԵȣ©À´È·¶¨VBP¡£
À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉç¸ß¼¶¸±×ܲá¢Éñ¾ÏµÍ³¼²²¡Ñз¢ÒµÎñ×ܲüæÈ«Çò°¢¶û´Äº£Ä¬²¡ÂôÁ¦ÈË¡¢À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÃÀ¹ú¶Ê³¤¼æÊ×ϯִÐйÙIvan CheungÌåÏÖ£º¡°À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾µÄÄ¿±êÊǵÞÔìÐÂÁÆ·¨£¬ºÃ±ÈÎÒÃǵĿ¹¦Âµí·ÛÑùÔÏËά¿¹ÌåLecanemab£¬Õâ¿ÉÄÜÓÐÖúÓÚ¼õÇá°¢¶û´Äº£Ä¬²¡»¼Õß¼°Æä¼ÒÈ˵Ľ¹ÂÇ¡£¶ÔÓÚ°¢¶û´Äº£Ä¬²¡£¬ÖØÒªµÄÊÇÆÀ¼ÛÁÆ·¨µÄÕûÌå¼ÛÖµ£¬²»½öÒª¿¼ÂÇÒ½ÁƳɱ¾£¬»¹Òª¿¼ÂǾ޴óµÄÉç»á³É±¾¡£×÷ΪÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¡°ÌåÌùÈËÀཡ¿µÊ¹Ãü¡¢ÐÅÈκÍ͸Ã÷¶È¡±ÔÊÐíµÄÒ»²¿ÃÅ£¬ÎÒÃǽ«¼ÌÐøÐû²¼ÓйØLecanemabµÄÊý¾ÝºÍÐÅÏ¢£¬²¢ÆÚ´ý½ñÄêÇï¼¾Äܹ»·ÖÏíLecanemabÑéÖ¤ÐÔIIIÆÚClarity ADÁÙ´²ÊÔÑéµÄ½á¹û¡£¡±
À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÓÚ2022Äê5ÔÂÔÚ¼ÓËÙÅú׼ͨµÀÏÂÍê³ÉÏòFDA¹ö¶¯Ìá½»LecanemabÖÎÁÆÔçÆÚADµÄÉúÎïÖÆÆ·Ðí¿ÉÉêÇ루BLA£©¡£LecanemabÖÎÁÆÔçÆÚADµÄIIIÆÚClarity ADÁÙ´²Ñо¿ÕýÔÚ½øÐÐÖУ¬²¢ÓÚ2021Äê3ÔÂÍê³ÉÕÐļ£¬¹²Èë×é1795Ãû»¼Õß¡£Clarity ADÑо¿µÄÖ÷ÒªÖÕµãÊý¾Ý½«ÓÚ2022ÄêÇï¼¾Ðû²¼¡£FDAÒѾͬÒ⣬ÔÚClarity ADÑо¿Íê³Éºó¿É½«ËùµÃ½á¹û×÷Ϊȷ֤ÐÔÑо¿µÄ½á¹û£¬ÒÔÑéÖ¤LecanemabµÄÁÙ´²»ñÒæ¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¿ÉÄÜÓÚ2022²ÆÄêÄÚ£¨½ØÖÁ2023Äê3Ô£©ÏòFDAÌá½»LecanemabµÄÈ«ÃæÅú×¼ÉêÇ루¾ßÌåÈ¡¾öÓÚClarity ADÁÙ´²ÊÔÑéµÄ½á¹û£©¡£2022Äê3Ô£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¿ªÊ¼ÔÚÈÕ±¾Æ¾¾ÝÊÂÏÈÆÀ¹À×ÉѯÖƶÈÏòÒ©Æ·ºÍÒ½ÁÆÆ÷е¹ÜÀí¾Ö£¨PMDA£©Ìá½»ÉêÇëÊý¾Ý£¬ÒÔʹLecanemab¾¡Ôç»ñÅú£¬²¢½«Æ¾¾ÝÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾2022²ÆÄêÄÚClarity ADÑо¿µÄ½á¹ûÉêÇëÉú²úºÍÉÏÊÐÐí¿É¡£ÁíÍ⣬ƾ¾ÝClarity ADÑо¿µÄ½á¹û£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¼Æ»®ÓÚ2022²ÆÄêÔÚÅ·ÖÞÌá½»ÐÂÒ©ÉêÇë¡£
±¾ÐÂΟåÌÖÂÛµÄÊÇÕýÔÚ¿ª·¢µÄÒ©ÎïµÄÑо¿ÓÃ;£¬ÎÞÒâת´ï¹ØÓÚÁÆЧ»òÄþ¾²ÐԵĽáÂÛ¡£ÎÒÃDz¢²»±£Ö¤´ËÊÔÑéÓÃÒ©ÎｫÀÖ³ÉÍê³ÉÁÙ´²¿ª·¢»ò»ñµÃÎÀÉúÕþ¸®µÄÅú×¼¡£
*ADµÄ³ß¶ÈÖÎÁÆ£¨SoC£©Ä¿Ç°°üÂÞÉú»î·½Ê½µ÷ÕûºÍÖ¢×´µÄÒ©ÎïÖÎÁÆ¡£
**ÖÊÁ¿µ÷ÕûÉúÃüÄ꣨QALY£©ÊÇÒ»ÖÖºâÁ¿½¡¿µ½á¾ÖµÄÖ¸±ê¡£ÓÉÓÚ½¡¿µÊÇÉúÃü³¤¶È£¨¼´ÊýÁ¿£©ºÍÉú»îÖÊÁ¿£¨QOL£©µÄº¯Êý£¬QALYµÄ·¢ÉúÔòÊÇΪÁ˽«ÕâЩÊôÐÔµÄÖµºÏ²¢ÎªÒ»¸ö¸öÌåÖ¸Êý¡£Ò»¸öQALY¼´ÊÇ´¦ÓÚÍêÈ«½¡¿µ×´Ì¬µÄÒ»Äê¡£QALYÆÀ·Ö·¶Î§´Ó1£¨ÍêÈ«½¡¿µ£©ÖÁ0£¨ËÀÍö£©¡£ÀýÈ磬һÏîеĸÉÔ¤´ëÊ©¿ÉÄÜ»áÔö¼Ó3ÄêµÄÊÙÃü£¬²¢½«Éú»îÖÊÁ¿¸ÄÉÆ70%£¨QALYÆÀ·ÖΪ2.1£©£¬¶øÏÖÓеĸÉÔ¤´ëÊ©¿ÉÄÜ»áÔö¼Ó3ÄêµÄÊÙÃü£¬µ«QOL ½ö¿É¸ÄÉÆ50%£¨QALYÆÀ·ÖΪ1.5£©£¬ËùÒÔÕâÏîиÉÔ¤´ëÊ©µÄÔöÁ¿QALY½«Îª0.6 QALY¡£
***ÕýʽºÍ·ÇÕýʽ»¤ÀíÓöȲ»°üÂÞLecanemabÒ©ÎïÓöȡ£
****ÔÚÇé¾°·ÖÎöÖÐ̽ÌÖÁËÌæ´úµÄÖÎÁÆÍ£Ö¹¹æÔò£¬¼´ÔÚ1.5Äê¡¢3ÄêºÍ5ÄêµÄÀιÌÆÚÏÞºóÍ£Ö¹LecanemabÖÎÁÆ¡£
*****ICERÊÇÃÀ¹úµÄÒ»¼Ò·ÇÓªÀûÐÔÑо¿×éÖ¯£¬×¨×¢ÓÚÆÀ¹À´¦·½Ò©¡¢Ò½ÁƲâÊÔ¡¢Æ÷еºÍÎÀÉúϵͳÌṩ´´ÐµÄÁÙ´²ºÍ¾¼Ã¼ÛÖµÖ¤¾Ý¡£
1 Kansal AR, Tafazzoli A, Ishak KJ, Krotneva S. Alzheimer’s disease Archimedes condition-event simulator: Development and validation.Alzheimers Dement (NY).2018;4:76-88.Published 2018 Feb 16. doi:10.1016/j.trci.2018.01.001.
2 Tafazzoli and Kansal. Disease simulation in drug development, External validation confirms benefit in decision making.The Evidence Forum.2018.
https://www.evidera.com/wp-content/uploads/2018/10/07-Disease-Simulation-in-Drug-Development_Fall2018.pdf
3 Tafazzoli A, Weng J, Sutton K, et al. Validating simulated cognition trajectories based on ADNI against 436 trajectories from the National Alzheimer’s Coordinating Center (NACC) dataset.11th edition of Clinical Trials on 437 Alzheimer’s Disease (CTAD); Barcelona, Spain: 2018.
4 Tahami Monfared AA, Tafazzoli A, Ye W, Chavan A, Zhang Q. Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer¡¯s Disease Using Simulation Modeling. Neurol Ther 11, 863¨C880 (2022). https://link.springer.com/article/10.1007/s40120-022-00350-y.
5 ICER Value Framework 2020-2023. 2022.ICER_2020_2023_VAF_02032022.pdf
6 Alzheimer’s Association. 2022 Alzheimer¡¯s Disease Facts and Figures 2022 Available from: alzheimers-facts-and- figures.pdf.
ýÌå×Éѯ£º
¹«¹²¹Øϵ²¿£¬
À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉç
+81-(0)3-3817-5120
À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÃÀ¹ú
Libby Holman
Libby_Holman@Eisai.com
201-753-1945
